Incidence of microvascular complications of type 2 diabetes: A 12 year longitudinal study from Karachi-Pakistan

Asher Fawwad¹, Nida Mustafa², Awn Bin Zafar³, Maria Khalid⁴

ABSTRACT

Objectives: To estimate the incidence of microvascular complications among subjects with type 2 diabetes at a tertiary care hospital.

Methods: This retrospective longitudinal follow-up study assessed the data records of type 2 diabetic subjects who visited the outpatient department of Baqai Institute of Diabetology and Endocrinology, Baqai Medical University, from January 2005 to April 2016. Subjects with gestational diabetes, type 1 diabetes and with history of any microvascular complication were excluded. Medical records were obtained through electronic database (Health Management System). Statistical analyses were conducted using STATA version 14 and SPSS version 20.

Results: The incidence of microvascular complications was 92.8, 106.2, and 130.2 per 1000 person per years for retinopathy, neuropathy and nephropathy respectively. Retinopathy, neuropathy and nephropathy were significantly high among diabetic patients with duration of diabetes >10 years followed by 5-10 years. Incidence of retinopathy and nephropathy was significantly higher in patients who had HbA1c>7% than patients with HbA1c≤7% (pvalue<0.05). Higher incidence rate of all three microvascular complications were seen in subjects with hypertension than subjects without hypertension.

Conclusion: A high incidence of microvascular complications is found in subjects with type 2 diabetes. Poor glycaemic control, longer duration of diabetes and hypertension was found to be associated with the occurrence of these complications.

KEYWORDS: Incidence rate, Microvascular complications, Type 2 diabetes.

doi: https://doi.org/10.12669/pjms.345.15224

How to cite this:
Fawwad A, Mustafa N, Zafar AB, Khalid M. Incidence of microvascular complications of type 2 diabetes: A 12 year longitudinal study from Karachi-Pakistan. Pak J Med Sci. 2018;34(5):1058-1063. doi: https://doi.org/10.12669/pjms.345.15224

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Diabetes mellitus is a global pandemic for the 21st century. Subjects with type 2 diabetes can have metabolic and vascular complications. Chronic complications can be classified as macrovascular or microvascular complications. Epidemiologic study has shown a fifth of all diabetes patients suffer from two or more micro vascular complications. The complications give rise to morbidity and compromise the quality of life for diabetic subjects. Long-term complications of diabetes include retinopathy with potential loss of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot ulcers, amputations, and Charcot joints; and autonomic neuropathy
causing gastrointestinal, genitourinary, and cardiovascular symptoms and sexual dysfunction. There are a number of internationally recognized guidelines, algorithms, and position statements for the diagnosis, control, and management of diabetes. However, implementation of guidelines for the management of diabetes has beneficial effects for the individual with diabetes, including a significant decrease in complications associated with type 2 diabetes.

The American Diabetes Association (ADA) has designated HbA1C level of <7% as a target to control blood glucose and International Diabetes Federation (IDF) has designated HbA1c of <6.5 for optimal blood glucose control. According to United Kingdom Prospective Diabetes Study (UKPDS) and Kumamoto study, risk of microvascular complications can be lowered after achieving adequate glycemic control. Similarly, a hypertensive subgroup analyzed in the UKPDS showed adequate control of blood pressure improves the outcome of both macrovascular and microvascular complications. At the age of 45, around 40% of subjects with type 2 diabetes are hypertensive, the proportion increasing to 60% by the age of 75. With the holistic approach, these complications can be controlled leading to reduction in morbidity, mortality and healthcare costs. The present study, therefore, aims to estimate the incidence of chronic microvascular complications in a large sample of type 2 diabetic subjects attending a tertiary care hospital.

METHODS

This retrospective longitudinal follow-up study assessed the data records of type 2 diabetic subjects visiting the outpatient department of Baqai Institute of Diabetology and Endocrinology (BIDE), Baqai Medical University, Karachi - Pakistan from January 2005 to April 2016. Subjects with gestational diabetes, type 1 diabetes and a history of any microvascular complications at first visit, were excluded. Medical records were obtained through electronic database (Health Management System). The records of subjects, included as per the inclusion criteria having no complication at baseline visit were followed for their follow up visits to document the development of any microvascular complication.

Retinopathy was labelled on finding the diagnostic signs of retinopathy on eye exam i.e., development of pre-proliferative & proliferative retinopathy, macular edema or diabetes-related blindness by direct fundoscopy. Neuropathy was diagnosed as per the standardized guidelines after checking pin prick, vibration sense, ankle reflex and knee reflex. Whereas, diagnosis of nephropathy was based on the findings of urinary albumin in urine detailed report, urinary micro albumin and 24 hours’ urine for protein and creatinine clearance. Blood pressure was measured by mercury sphygmomanometer in a sitting position by using standard method. Average blood pressure over the follow-up period was determined from the blood pressure recorded at each visit. Average blood pressure level ≤130/85 mmHg was taken as normal or controlled BP and average blood pressure level >130/85 mmHg was taken as high BP. Average HbA1c value of ≤7% and >7% were taken as good and poor control respectively. Average HbA1c was defined as the mean of all HbA1c values from baseline until the development of any microvascular complication or censoring. HbA1c was performed by HPLC method on BIO RAD D-10.

Statistical Analysis: The incidence of microvascular complications in the follow-up period was estimated by number of observed new microvascular complications cases per 1000 person per years. Follow up time (person-year) was calculated as the time elapsed from the date of registration till the date of microvascular complication development, or the end of follow-up, whichever came first. The calculation of 95% confidence interval for the incidence rate was based on the assumption that the observed incidence cases followed a Poisson distribution. Incidence were estimated by different intervals of duration of diabetes, glycemic control and blood pressure control. T-test and chi-square test were also applied to determine the significance. A two-sided P-value <0.05 was considered statistically significant. Statistical analyses were conducted using STATA version 14 and SPSS version 20.

Ethical approval: Study was approved from the Institutional Review Board of Baqai Institute of Diabetology and Endocrinology, Baqai Medical University.

RESULTS

A total of 4633 type 2 diabetic subjects were included in this study. Among them 2336 (50.4%) were male and 2297(49.6%) were female. Large
number of subjects (55.7%) had duration of diabetes >5 years. At baseline, 3175 (85.9%) of the subjects had HbA1c level >7% and 1976 (57.2%) were hypertensive (Table-I).

The incidence of microvascular complications was 92.8, 106.2, and 130.2 per 1000 person per years for retinopathy, neuropathy and nephropathy respectively. The incidence rate ratio (IRR) shows that retinopathy, neuropathy, and nephropathy were significantly higher among diabetic patients with duration of diabetes >10 years followed by 5-10 years (Table-II).

Incidence of retinopathy and nephropathy was significantly higher in patients who had HbA1c>7% (IRR of retinopathy= 2.89; IRR of nephropathy =1.53, p-value<0.001) than patients with HbA1c≤7%. Similar trend was observed in neuropathy however, the difference was not significant (Table-II).

Furthermore, it was identified that incidence of all microvascular complications i.e. retinopathy, nephropathy and neuropathy was significantly higher among diabetics with hypertension (IRR of

**Table-I: Basic and Clinical Characteristics.**

| Variables                  | Female | Male     | P-value | Overall |
|----------------------------|--------|----------|---------|---------|
| N                          | 2297   | 2336     | -       | 4633    |
| Age (years)                | 50.7±10.26 | 50.68±11.22 | 0.938   | 50.69±10.76 |
| BMI (kg/m²)                | 29.28±5.58 | 27.35±4.75  | <0.0001 | 28.29±5.26  |
| **Duration of diabetes**   |        |          |         |         |
| <5 years                   | 968(42.1%) | 1086(46.5%) | 2054(44.3%) |
| 5-10 years                 | 700(30.5%) | 647(27.7%)  | 1347(29.1%) |
| >10 years                  | 629(27.4%) | 603(25.8%)  | 1232(26.6%) |
| **Family history of diabetes** |     |          |         |         |
| Yes                        | 1210(71.1%) | 1209(67.7%) | 0.028   | 2419(69.4%) |
| No                         | 491(28.9%)  | 577(32.3%)  | 1068(30.6%) |
| **Smoking history**        |        |          | <0.0001 |         |
| Current smoker             | 6(0.4%)   | 302(17%)   |         | 308(8.9%)  |
| Never Smoked               | 1682(99.6%) | 1477(83.0%) |         | 3159(91.1%) |
| **Alcohol history**        |        |          |         |         |
| Current drinker            | 1(0.1%)   | 18(1.0%)   | <0.0001 | 19(0.6%)   |
| Never drink                | 1682(99.9%) | 1746(99.0%) |         | 3428(99.4%) |
| **Hypertension status**    |        |          | <0.0001 |         |
| Yes                        | 1047(62.2%) | 929(52.4%)  |         | 1976(57.2%) |
| No                         | 635(37.8%)  | 844(47.6%)  |         | 1479(42.8%) |
| **HbA1c (%)**              |        |          |         |         |
| ≤7%                        | 237(13.2%) | 283(14.9%)  | 0.139   | 520(14.1%) |
| >7%                        | 1558(86.8%) | 1617(85.1%) |         | 3175(85.9%) |
| Cholesterol (mg/dL)        | 183.36±43.76 | 175±45.08   | <0.0001 | 178.96±44.65 |
| HDL (mg/dL)                | 40.11±10.15 | 36.65±8.29  | <0.0001 | 38.29±9.38  |
| LDL (mg/dL)                | 111.83±35.05 | 106.83±33.06 | <0.0001 | 109.2±34.1  |
| Creatinine (mg/dL)         | 0.94±0.43   | 1.1±0.36    | <0.0001 | 1.02±0.41   |
| Triglyceride (mg/dL)       | 176.26±127.76 | 181.22±139.73 | 0.348   | 178.88±134.21 |

Data presented as mean±SD or n (%).
P-value <0.05 was considered statistically significant.
Table-II: Incidence of Microvascular complications according to duration of diabetes, HbA1c level, Hypertension status.

| Duration of Diabetes | Follow up time (personyear) | Development of Microvascular complication | Incidence density (1000 personyear) | IRR (95% C.I) | P-value |
|----------------------|-----------------------------|-------------------------------------------|-------------------------------------|---------------|---------|
| **Retinopathy**      |                             |                                           |                                     |               |         |
| <5 years             | 1226.997                    | 49                                        | 39.93                               | 1             | <0.0001 |
| 5-10 years           | 573.48                      | 60                                        | 104.62                              | 2.61(1.76-3.90)| <0.0001 |
| >10 years            | 578.784                     | 112                                       | 193.5                               | 4.84(3.43-6.92)| <0.0001 |
| **Neuropathy**       |                             |                                           |                                     |               |         |
| <5 years             | 3390.25                     | 360                                       | 106.18                              | 1             |         |
| 5-10 years           | 1682.23                     | 239                                       | 142.07                              | 1.33(1.13-1.58)| 0.0006  |
| >10 years            | 1065.41                     | 200                                       | 187.72                              | 1.76(1.47-2.10)| <0.0001 |
| **Nephropathy**      |                             |                                           |                                     |               |         |
| <5 years             | 4927.66                     | 446                                       | 90.5                                | 1             |         |
| 5-10 years           | 3251.65                     | 357                                       | 109.79                              | 1.21(1.05-1.39)| 0.0068  |
| >10 years            | 2589.98                     | 341                                       | 131.66                              | 1.45(1.25-1.67)| <0.0001 |
| **Average HbA1c**    |                             |                                           |                                     |               |         |
| ≤7%                  | 262.424                     | 9                                         | 34.29                               | 1             | 0.0003  |
| >7%                  | 2102.134                    | 209                                       | 99.42                               | 2.89 (1.498 -6.428)|         |
| **Average blood pressure** |                      |                                           |                                     |               |         |
| ≤130/85 mmHg        | 1356.099                    | 105                                       | 77.42                               | 1             | 0.0047  |
| >130/85 mmHg        | 1023.162                    | 116                                       | 113.37                              | 1.46 (1.114-1.925)|         |
| **DISCUSSION** The rising incidence of diabetes related complications poses a major clinical, societal |

retinopathy=1.46; IRR of neuropathy=1.30; IRR of nephropathy= 1.30, pvalue<0.005) than diabetics without hypertension (Table-II).
and economic burden not only in high-income countries but also in developing countries. Various epidemiological studies have reported the role of several risk factors for progression of diabetes complications. However, there is a paucity of data regarding incidence of diabetes complication while the role of different risk factors for developing these complications are somewhat well understood in developing countries like Pakistan. This retrospective cohort study revealed the incidence of diabetes related microvascular complications in subjects attending a tertiary care unit in Karachi, Pakistan. This study reported incidence rate of 92.9, 130.2 and 106.2 per 1000 person per years for retinopathy, neuropathy and nephropathy respectively. These figures are high as compared to the findings of other regional and international studies. The reason for high incidence is that the current study is from a tertiary care unit having more subjects with longer duration of diabetes. Further larger scale prospective and epidemiological studies are required to ascertain the findings of this study.

It is well documented in previous studies of India, Bangladesh, UAE, Egypt, and England that microvascular complications advance with duration of diabetes. The current study provided consistent outcomes of higher incidence of all three microvascular complications with the increasing duration of diabetes. Similar results were also observed in our previous study reporting high prevalence of microvascular complications with the advancement of duration of type 2 diabetes.

Poor glycemic control has been considered as a major risk factor for microvascular complications. In this study, the incidence of microvascular complications (retinopathy and nephropathy) were significantly higher among type 2 diabetic subjects with uncontrolled HbA1c (HbA1c > 7%). Likewise, studies from Japan and Taiwan found significantly increased incidence of microvascular complications with higher levels of HbA1c. The trend for the development of neuropathy and incidence although shows the similar finding but it does not reach the level of significance. Authors from Lahore, Pakistan reported the same phenomenon that neuropathy was not significantly prevalent in subjects with uncontrolled diabetes. Using more advanced and sensitive gadgetries might improve the screening and thus their relationship with diabetes control can be ascertained in an improved manner.

Control of blood pressure is another important hallmark in the management of type 2 diabetes to improve the mortality and morbidity. We observed strong and significant association of blood pressure control with retinopathy, neuropathy and nephropathy. Other regional and international studies are also in agreement with our finding.

Strengths and limitations of the present study included its large sample size with 12 years follow-up to assess the incidence and occurrence of microvascular complications, probably first time from Pakistan. In the absence of community based epidemiological studies this data can be considered as a representative but future prospective and epidemiological studies are required to ascertain the findings of this study.

CONCLUSION

A high incidence of microvascular complications is found in subjects with type 2 diabetes. Poor glycaemic control, longer duration of diabetes and hypertension was found to be associated with the occurrence of these complications.

ACKNOWLEDGMENT

The authors would like to acknowledge the significant contribution made by Prof. Rubina Hakeem, Dr. Musarrat Riaz and Prof. Abdul Basit for this research project.

Funding: None.

Conflict of interest: None.

REFERENCE

1. Hurst C, Thinkhamrop B. The Association between Hypertension Comorbidity and Microvascular Complications in Type 2 Diabetes Patients: A nationwide cross-sectional Study in Thailand. Diabetes Metabolism J. 2015;39(5):395-404. doi: 10.4093/dmj.2015.39.5.395.
2. Basit A, Hydrie MZ, Hakeem R, Ahmedani MY, Masood Q. Frequency of chronic complications of type 2 diabetes. J Coll Phys Surg Pak. 2004;14(2):79-83.
3. Pandit A. Study of Complication Profile in Type 2 Diabetes Mellitus Patients at First Visit to Tertiary Care Clinic in Central Indian Context. Int J Health Sci Res. 2016;6(6):46-49.
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81-S90. doi: 10.2337/dc14-S081.
5. Home P, Haddad J, Latif ZA, Soewondo P, Benabbs Y, Littwak L, et al. Comparison of national/regional diabetes guidelines for the management of blood glucose control in non-western countries. Diabetes Therapy. 2013;4(1):91-102. doi: 10.1007/s13300-013-0022-2.
6. Ali A, Iqbal F, Taj A, Iqbal Z, Amin MJ, Iqbal QZ. Prevalence of Microvascular Complications in Newly Diagnosed Patients with Type 2 Diabetes. Pak J Med Sci. 2013;29(4):899-902. doi: 10.12669/pjms.294.3704
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-209. doi: 10.2337/dc08-0025.

8. Basit A, Hydrie MZ, Hakeem R, Ahmedani MY, Waseem M. Glycemic control, hypertension and chronic complications in type 2 diabetic subjects attending a tertiary care centre. J Ayub Med Coll. 2005;17(2):1-6.

9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703.

10. Ahsan S, Basit A, Ahmed KR, Ali L, Khanam R, Fawwad A, et al. Risk indicators of diabetic retinopathy in patients with type 2 diabetes screened by fundus photographs: a study from Pakistan. Int J Diabetes Dev Ctries. 2015;35(3):333-338. doi: 10.1007/s13410-014-0277-9.

11. Lin YC, Thuy TD, Wang SY, Huang PL. Type 1 diabetes, cardiovascular complications and sesame. J Tradit Complement Medi. 2014;4(1):36-41. doi: 10.4103/2225-124817.

12. Bansal D, Gudala K, Esam HP, Nayakallu R, Vymusani RV, Bhansali A. Microvascular complications and their associated risk factors in newly diagnosed type 2 diabetes mellitus patients. Int J Chronic Dis. 2014; 2014. doi: 10.1155/2014/201423.

13. Agrawal R, Ola V, Bishnoi P, Gothsold S, Sirohi P, Agrawal R. Prevalence of micro and macrovascular complications and their risk factors in type-2 diabetes mellitus. JAPI. 2014;62:505. Incomplete

14. Inassi J, Vijayalakshmy R. Role of duration of diabetes in the development of nephropathy in type 2 diabetic patients. Natl J Med Res. 2013;3(1):5-8.

15. Morkrid, Kjersti, Ali L, Hussain A. Risk Factors and Duration of Diabetes and Prognostic Factors of Type 2 Diabetes Mellitus. J Ayub Med Coll. 2005;17(2):1-6.

16. Al-Kaabi JM, Al Maskari F, Zoubeidi T, Abdulle A, Shah SM. Prevalence and determinants of peripheral neuropathy in patients with type 2 diabetes attending a tertiary care center in the United Arab Emirates. J Diabetes Metab. 2014;5(346):2. doi: 10.4172/2155-6156.1000346.

17. Kasim K, Ammar M, El Sadek AA, Gawad SA. Peripheral neuropathy in type-II diabetic patients attending diabetic clinics in Al-Azhar University Hospitals, Egypt. Int J Diabetes Mellitus. 2010;2(1):20-23. doi: 10.1016/j.ijdm.2009.10.002.

18. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35(3):592-596. doi: 10.2337/dc11-1043.

19. Kawasaki R, Tanaka S, Yamamoto T, Sone H, Ohashi Y, Akanuma Y, et al. Japan Diabetes Complications Study Group. Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study. Diabetologia. 2011;54(9):2288-2294. doi: 10.1007/s00125-011-2199-0.

20. Reed C, Hong J, Novick D, Lenox-Smith A, Happich M. Incidence of diabetic peripheral neuropathic pain in primary care—a retrospective cohort study using the United Kingdom General Practice Research Database. Pрагmat Obс Res. 2013;4:27-37. doi: 10.2147/POR.S49746.

21. Chisya Y, Terefe W, Assefa H, Lakew S. Prevalence and factors associated with diabetic retinopathy among diabetic patients at Arbaminch General Hospital, Ethiopia: Cross sectional study. PloS One. 2017;12(3):e0171987. doi: 10.1371/journal.pone.0171987.

22. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, et al. Progression to overt nephropathy in type 2 diabetes. Diabetes Care. 2003;26(7):2150-2155. doi: 10.2337/diabcare.26.7.2150.

23. Wu TE, Chen YH, Chen HS. Effects of glucose and blood pressure control on diabetic kidney disease in old patients with type 2 diabetes. Diabetol Metabol Syndro. 2014;6(1):81. doi: 10.1186/1758-5996-6-81.

24. Zafar AB, Ahmed J, Basit A, Alvi SF, Fawwad A, Riaz M. Factors screening the peripheral neuropathy in asymptomatic patients with type 2 diabetes by Neurothesiometer. J Diabetol. 2014;3(2):1-6.

25. Grossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovas Diabetol. 2017;16(1):3. 10.1186/s12933-016-0485-3

26. Xu J, Xu L, Wang YX, You QS, Jonas JB, Wei WB. Ten-year cumulative incidence of diabetic retinopathy. The Beijing Eye Study 2001/2011. PloS One. 2014,9(10):e111320. doi: 10.1371/journal.pone.0111320.

Authors’ Contributions:

FA: Concept and design, undertook the data analyses, edited and revised the manuscript.

MN: Interpretation of data, prepared and reviewed the manuscript.

ZAB: Edited and revised the manuscript.

KM: Prepared and reviewed the manuscript.